GlobeNewswire

Striving for Gold - Laying the Groundwork for the Olympic Healthcare Interoperability Initiative

Dela

LAS VEGAS, Nev., March 06, 2018 (GLOBE NEWSWIRE) -- The spirit of health and well-being is core to the founding principles of the Olympic Games and heralds the tenets of sustainable social development within each host and participating country. With the ambitious goal of integrating advanced digital health information sharing into health services provided before, during, and after the Games, the Olympic Healthcare Interoperability (OHI) Initiative & OHI Foundation have been formed to aggressively pursue this vision.

OHI, a digital health industry initiative with charter sponsorship from not-for-profit organizations HIMSS and SNOMED International, was created to advance the seamless exchange and use of health information globally through the Olympic Games. Starting with the 2020 Summer Games in Tokyo, OHI's goal is to "showcase the possible" and "implement the real", through the communication of digital health information, for the benefit of the 1,000's of athletes, trainers and staff, volunteers and attendees. With each edition of the Games, a digital health legacy will be crafted to establish a comprehensive, world-wide infrastructure supportive of appropriate access to relevant clinical information...anywhere, at any time.

Utilizing the latest innovations in digital health, OHI will connect pre-Games, person-specific healthcare information with information generated at the Games by Olympic and Host City healthcare service providers, which will flow back around the world with each individual once the Games conclude. OHI's initial scope will include patient identity matching and access to international patient summaries with capacity to include the significant facets of a patient's digital health record over time.  All with the needed security, privacy and consent framework that will ensure appropriate access to all information.

Consider the case of a Jamaican athlete collapsing on the track, showing symptoms of cardiac stress.  Medical personnel at the stadium use an electronic medical record (EMR) system to query the athlete's electronic records from Jamaica, and discover a number of allergies, current medications, and medical conditions to inform a treatment plan. The athlete, requiring a surgical procedure and transferred to the host city's tertiary hospital, is followed by the necessary diagnostic and treatment information via OHI interoperability.  Post surgery, the updated medical record is posted to the athlete's Jamaican EMR system for follow-up medical treatment at home.

As a way to build an Olympic digital health ecosystem that includes all stakeholders willing to specify, prototype and deploy digital health technology, the OHI Foundation has been created as a not-for-profit, charitable organization.  The Foundation itself has no restriction on membership, and welcomes the participation and support of the global digital health community, namely vendors, healthcare providers, industry and standards organizations.

Recognized charter supporters, HIMSS and SNOMED International, lend their commitment to the pursuit of quality and safety improvements through health information technology and standards alike. Hal Wolfe, HIMSS CEO, states that "HIMSS is proud to sponsor the OHI Initiative as a representative of the digital health industry globally.  OHI supports an ecosystem at the Olympic Games that is built on the same standards, products and infrastructures that are being implemented around the world in order to deliver better health through information and technology. our industry is dedicated to the realization of that vision." Don Sweete, CEO, SNOMED International,  echoes that sentiment. "At the core of care delivery is the principle that clinicians can, beyond a shadow of a doubt, rely on available, accessible and unambiguous clinical information at any point of service. Demonstrating this critical relationship at work through OHI and in support of the healthcare program offered at each Olympic Games, we see a forward-looking example made possible by the interoperability of health information."

Michael Nusbaum, OHI's Executive Lead, has been a driving force in realizing the OHI vision. "Launching OHI through this year's HIMSS18 Interoperability Showcase speaks to the promise of global healthcare interoperability delivered through the lens of the Olympic Games, and for the benefit of participants, national teams, and host countries."

Interested parties can learn more about this initiative at a presentation and drinks reception Tuesday March 6, 4:30pm - 5:30pm  at the HIMSS Interoperability Showcase Theatre, and at an educational session Wednesday March 7th, 1:00pm - 2:00pm in Murano 3301.  Organizations and individuals interested in becoming an OHI Foundation partner are invited to visit the OHI kiosk at the Interoperability Showcase.

About OHI:
OHI, the Olympic Healthcare Interoperability Initiative, began early in 2017 to advance the seamless exchange and use of health information globally, leveraging the 2-year cadence of the Olympic Games and established international standards. Utilizing the latest innovations in digital health, OHI will connect pre-Games person-specific healthcare information with information generated at Games time by Olympic and Host City healthcare service providers: from athletes to staff/officials to volunteers to spectators.

The OHI Foundation is a not-for-profit, charitable organization based in the U.S. The Foundation provides the facilitation and management services required to progress its vision of advancing the use of digital health technology in conjunction with the Olympic Games to impact the health of individuals around the world. 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0abf3f67-1fe7-43ac-ba17-1a58759b3431

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/49164c85-434e-4f60-bb85-d2ecdf2282de

Michael Nusbaum
Olympic Healthcare Interoperability Initiative 
+1 (250) 384-0001
michael@ohiinitiative.org



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Olympic Healthcare Interoperability Initiative via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum